



TSX: MBX | OTCQX: MBXBF

Microbix Presentation

Growth & Profits from Supporting
Next-Generation Diagnostics



Spring 2026



Forward-Looking Statements



This presentation contains forward-looking statements about trends and objectives.

Risks and uncertainties relating to such statements could cause actual outcomes to differ materially.

Such risks include, among others, those related to operations, customers or markets, growth drivers, products or technologies, product pricing or costs, development projects, financial results, regulatory matters, access to markets, and access to capital.

Forward-looking statements represent Microbix's current judgement, and it disclaims any obligation to update them except as required by applicable laws.



Microbix – Sales Growth Backed by a Strong Balance Sheet



<p>A global leader in infectious diseases and a trusted partner and supplier to the largest diagnostics companies globally.</p>	<p>Targeting annual sales growth of $\geq 20\%$ through f2028, per detailed MD&A disclosures</p>	<p>3 state-of-the-art facilities fully-commissioned, modern ERP & eQMS implemented, thereby providing capacity for $\geq \\$100M$ in sales</p>
<p>Multiple distinct, yet related, business lines & each well-positioned for growth</p>	<p>Multiple Net Earnings and EBITDA¹ positive quarters since 2021</p>	<p>Excellent Liquidity and Balance Sheet with Cash & Credit of ~C\$13M, D/E¹ of ~0.38 & Current Ratio¹ of ~7.5</p>
<p>F2025 Revenues of \$18.6M, Strong LT record of sales growth & product creation</p>	<p>Sizeable NCIB in place, repurchased & cancelled >10M shares since 2022</p>	<p>Strong Insider ownership of ~16%</p>

1 - Denotes non-GAAP financial measure, as defined in subsection 6.1(e) of National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure ("NI 52-112"). Please refer to the "Non-GAAP Measures" section in the appendix to this presentation for further information.

Financials – Microbix Capital Structure




TSX: MBX • OTCQX: MBXBF

Current Price	\$0.25 (2026-3-20)
Shares Outstanding (Basic)	138.8M **
(Fully Diluted)	169.6M **
52 Week High	\$0.45
52 Week Low	\$0.21
Market Cap	\$34.7M
Avg. Daily Volume	~106K (3 month)
Cash and Line of Credit	~\$13.1M **
Longer Term Debt	\$3.0M BDC & Govt.** \$4.0M debentures*

*Active Share Buyback Program (“NCIB”)
For up to 5% of issued & outstanding per year.*

**Convertible at \$0.23
** As of December 31, 2025*

Analyst Coverage



David Martin
Target Price: **\$0.50**



Bruce Krugel
Target Price: **\$0.55**

Microbix Senior Management



Cameron L. Groome *CEO, President, and Director*

Has served on the MBX BoD and AC since 2012 and was appointed CEO in 2017.

30+ years' experience in senior life sciences and capital markets roles.

Successful leader, executive, director, and advisor for public and private companies.

Jim Currie, CPA *Chief Financial Officer*

Joined MBX as CFO in 2016 after several CFO roles and a VP of Finance role at MDS SCIEX, a global leader in life science and analytical technologies.

Jim holds a Bachelor of Commerce, and both CPA and CMA designations.

Ken Hughes, Ph.D. *Chief Operating Officer*

Executive and biomedical scientist with 25 years of experience in biotech and pharma.

Previously was CEO of iTP Biomedica, VP of Sci. & Reg. Affairs at Innovative Medicines Canada, and Co-founder and Advisory Board member of PlantForm Corporation.

Phil Casselli *Sr. V.P. Business Dev., Sales, & Marketing*

Manages MBX's relationship with over 100 makers of infectious disease diagnostics across multiple regions.

He holds a Bachelor of Applied Science in Chemical Engineering and has more than 30 years' experience in the biotech and pharmaceutical industries.

Mark Luscher, Ph.D. *Senior Vice President, Scientific Affairs*

Responsible for scientific programs, he is a specialist in cell biology, immunovirology, and cytometry.

He is an inventor on numerous patents and patent applications and oversees scientific and technological programs and initiatives related to MBX's products.

20+ Other Skilled Directors & Managers, and a total of 120+ Staff

Including but not limited to:

Steven Hagerman – Senior Director of Operations, **Amer Alagic** – Director of R&D, **Daniel Costa** – Director of Manufacturing, **Bo Hollas** – Director, QA & Compliance, **Lucy Lin** – Director of QC, and **Pavel Zhelev** – Director, Product Management.

Microbix Board of Directors

STRONG ALIGNMENT WITH 22M INSIDER-OWNED SHARES



Martin Marino *Board Chairman*

Mr. Marino has 30+ years of experience in corporate legal roles and executive management functions, with emphasis on transaction-based corporate development.

He also has considerable experience in conflict resolution and litigation management.

Dr. Peter M. Blecher *Director*

Dr. Blecher, a longtime ER physician and pain specialist for ~25 years, has founded or led multiple successful health-related businesses.

He is now Managing Partner of the Durham Spine & Pain Institute and is a credentialed pain practitioner with both the American and Canadian Academies of Pain Medicine.

Mark A. Cochran, Ph.D. *HRGC Chair*

Dr. Cochran was Executive Director of Johns Hopkins Medicine.

His experience spans all levels of the drug discovery and development value chain, including operational and executive roles in the healthcare, venture capital, pharmaceutical, and biotech industries.

Vaughn C. Embro-Pantalony *AC Chair*

Mr. Embro-Pantalony has held senior roles in life sciences at Bayer, Novopharm, and Terra, with a focus on licensing, business development, strategy.

He is a Chartered Director and Audit Committee Certified through McMaster University.

Joe Renner *Director*

- Mr. Renner, Chairman of Zydus Pharmaceuticals, of Pennington, New Jersey, has more than 30 years' experience in the pharmaceutical industry.
- He has enjoyed a successful career leading businesses with many drug approvals in the United States.

Jennifer Stewart *Director*

Ms. Stewart is the founder, President, & CEO of Syntax Strategic, a leading Canadian advocacy & communications firm.

She is a recognized expert in the field & actively engaged in media, business, & community initiatives.

Cameron Groome *Director*


Mr. Groome is CEO and President of Microbix.

What Microbix Makes and Sells




We grow, purify, and inactivate many bacteria and viruses to make “Antigens,” as critical ingredients in “Immunoassay” tests that detect antibodies in blood in order to assess exposure to, or immunity against, pathogens.

Antigen C\$ Sales



We create, make, and sell safe and stable mimetics of clinical patient-samples – as test-controls. Called quality assessment products (QAPs™), these medical devices are used to help make certain tests and test processes work reliably – to avoid “false negative” or “false positive” results.

QAPs C\$ Sales



Test Ingredients – Antigens



Grows, purifies, and inactivates native bacteria and viruses for use as antigens for more than 100 leading international diagnostic companies. Microbix provides antigens on a large scale for major international diagnostic manufacturers, most often as a critical sole-source supplier.

-  ToRCH Antigens – Worldwide commercial leader
-  Respiratory Antigens – Broad range of pathogens
-  Childhood Disease Antigens – Unique offerings
-  Sexually Transmitted Infections – Full range
-  Tropical Disease Antigens – Insect-borne pathogens



Test Controls – Quality Assessment Products (QAPs™)



QAPs Competitive Advantages



Performance

Full-genome & whole-workflow, to best prevent systemic errors across all platforms



Formats

Liquid vial, FLOQSwab®, & FFPE* formats to enable support of both lab-based & point-of-care testing



Stability

Proven LT stability at room temp (swabs & FFPE) or at 2-8°C (vials) for up to two years



Multiplexing

Multiple pathogens in one QAP to support next-gen multiplex test-platforms




Resistance/Variants

Supporting tests for viral variants and for anti-microbial resistant strains



Intellectual Property

Defended by issued or pending patents of both Microbix and Copan



To Whom Microbix Sells



Microbix has been selling to international test makers for decades – its Antigens forming the heart of millions of Immunoassays. It has over 100 such customers, many ordering > C\$ 100K/yr of product.

Over recent years, Microbix has added new categories of customers via its QAPs, expanding its addressable markets to include:

- Agencies that test the proficiency of clinical laboratories
- International makers of molecular and antigen tests
- Clinical laboratories in Canada, the U.S., and internationally

Disclosed relationships include the following companies:



Ensuring Confidence in Diagnostic Tests

Makers, Regulators, Users, & Payors Need Proof They Work



Our Products Help Ensure that Tests Actually Work. This is Critical for Correct Diagnosis and Treatment

Microbix makes essential products that enable diagnostic tests to be made and sold. Many next-generation Dx assays need Microbix products for approval & reimbursement.



Kinlytic[®] – An FDA-Approved Clot-Buster Drug




Microbix owns the BLA of a well-established thrombolytic.

Partnered with Sequel Pharma, LLC for re-launch of cell-culture derived LMW urokinase

Kinlytic[®] Urokinase

Microbix's deep expertise in cell-culturing led to its securing rights to a clot-buster biological drug approved in the U.S. & Canada (used for clearing venous catheters & pulmonary emboli).

- ✓ To resume sales, production at a new site must be validated as equivalent to past batches.
- ✓ A path to market has been settled with U.S. FDA, with CDMOs to make drug substance & drug product.
- ✓ The U.S. monopoly market (for tPA) is ~US\$ 400M just for the catheter clearance sub-indication.*



*Please see the Microbix MD&A and AIF for market-data reference information.

Kinlytic[®] – An FDA-Approved Clot-Buster Drug



Refined project scope to
Catheter Clearance Indication &
U.S. market as initial value-driver

Established Precise Costs
Quotes from qualified vendors
Removed risk for partners

Prepared Due Diligence
Data Room & detailed project Plans
~ 3.5 years to market post-funding

In 2024, Secured funding of
~US\$ 35M to fully underwrite
project cost & risk

Sequel Pharma, LLC has the funding and technical expertise to help return Kinlytic to market, providing a large additional opportunity – For **one-time milestone payments** of up to US\$ 31 million, and **ongoing royalties** targeted to be a double-digit percentage of net sales.

Operations – Capabilities and Highlights



We Have Built Both Capabilities and Capacity To Secure New Product & Customer Opportunities

Microbix now has over 120 staff across 3 adjacent sites

CE Mark and/or FDA Registrations for ~100 IVD “REDx” Molecular Test Controls and ~300 SKUs in total

265 Watline (building 1) wholly-owned and fully-licensed CL2+ Dx biologicals manufacturing facility

- ⊕ Culturing a wide range organisms at industrial scale
- ⊕ Full capabilities for production, QC, and QA of Antigens and QAPs
- ⊕ State-of-the-art infectious diseases expertise, including in-house synthetic biology capabilities



Operations – Capabilities and Highlights



We Have Built Both Capabilities and Capacity To Secure New Product & Customer Opportunities

235 Watline (building 2) built-out and operational

- ⊕ Semi-auto liquid-vial format QAPs Mfg. suite – 150,000/month capacity
- ⊕ Semi-auto dried-swab format QAPs Mfg. suite – 200,000 swabs/month capacity

275 Watline (building 3) built-out & operational

- ⊕ Fully-automated high-capacity line for reagents production
- ⊕ Further 2,000 ft² Product Development & QC Lab Space

Corporate Capabilities & Infrastructure

- ⊕ Sophisticated HR & Organizational Infrastructure
- ⊕ R&D, Customer Service, IT, & Synthetic Biology Capabilities
- ⊕ Electronic QMS (MasterControl) & ERP (NetSuite)




Operations - Expanding Product Line & Revenue



Microbix's product line is rapidly expanding, as is our base of customers. Just in the past few months...





- ⊕ **December 2025** – Alliance with Sekisui Diagnostics for QAPs to support new point-of-care instrument and assays in the United States.
- ⊕ **December 2025** – Alliance with Seegene Mexico for QAPs to support cervical cancer screening programs in nation of ~130 million people.
- ⊕ **January 2026** – Commercialized recombinant SARS-CoV-2 capsid antigen for use in QAPs and inclusion in Microbix product catalogue.
- ⊕ **February 2026** – In Finland, presented results of Molecular Pathology controls – to help ensure accuracy of infection-driven cancers.
- ⊕ **February 2026** – Welcomed The College of American Pathologists (CAP) as a QAPs client – to support multiple EQA/PT programs.
- ⊕ **March 2026** – For Kinlytic urokinase clot-buster drug redevelopment, modernized “Drug Substance” manufacturing methods.
- ⊕ **March 2026** – At *EUROGIN*, presented new HPV reference-materials to support cervical cancer screening based on self-collected samples.



Financials – The Past Several Years



Strong Revenues, Current Ratio¹, Net Earnings, and EBITDA¹ Have Repurchased (& cancelled) over 10 Million Shares




⊕ Financial Results – 2021 to 2026

¹ - Denotes non-GAAP financial measure, as defined in subsection 6.1(e) of National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure (“NI 52-112”). Please refer to the “Non-GAAP Measures” section in the appendix to this presentation for further information.

Microbix's Business Objectives – The Next Few Years




Cross-Selling – Sell every product category across existing customer-base of >100 Dx industry firms.



MDx & PoCTs – Support growth of Molecular & point-of-care-testing via value-added product lines.



New Clients – Identify & secure new Dx industry clients with over C\$ 1 M per year sales potential.



Multiplex Tests – Support industry's move into multi-analyte tests for “syndromic” diagnoses.



New Product Classes – Creating or acquiring new product lines, across user and test categories.



Resistance/Variant Tests – Supporting tests for viral variants and for antimicrobial resistance.

Key Takeaways about Microbix



Cutting-Edge Capabilities & Real Revenue Growth Opportunities

Both Dx & Rx Projects Self-Funding with Great Prospects

Expanding Earnings Potential to Drive Share Price Appreciation

Key Partner & Supplier to EQA/PT providers, Dx Makers, & Labs

Microbix has become a “go-to” partner regarding next-generation diagnostic tests. Its QAPs are often essential for approval/adoption of new lab-based and Point-of-Care tests.

Capabilities

- ⊕ Biology & Mfg.
- ⊕ QC/QA/Regulatory
- ⊕ Biz Dev & Mgmt

Goals

- ⊕ +Δ Revenues
- ⊕ +Δ Earnings
- ⊕ +Δ Share Value





Thank You



Cameron Groome

CEO, President, and Director

cameron.groome@microbix.com

Appendix regarding non-GAAP Financial Measures



This appendix provides important context concerning the non-GAAP financial measure “EBITDA” referenced on slides 3 and 18 earlier herein.

Non-GAAP (non-IFRS) Measures Discussion

In addition to disclosing detailed operating results in accordance with generally-accepted accounting principles (GAAP), Microbix provides supplementary non-GAAP financial measures to consider in evaluating the company’s operating performance such as EBITDA.

EBITDA represents net earnings of the company before the deduction of the expenses of interest, taxes, depreciation and amortization, with all such terms other than EBITDA as defined by International Reporting Standards (IFRS). EBITDA however is not a formally-defined term under IFRS or by GAAP.

Management believes the EBITDA (non-GAAP) financial measure may assist investors in assessing an investment in the Company’s shares given that it may provide additional insight into the Company’s financial performance, particularly for those investors who may regularly review the results of companies partially based on this informal yet widely-used financial measure.

All readers, regardless of their level of sophistication, are cautioned that EBITDA is not a formally-defined performance measure, does not have any standardized meaning under IFRS, and may differ from similar computations as reported by other similar entities. Accordingly, the EBITDA reported herein by Microbix may not be comparable to this measure as reported by other entities. EBITDA should therefore not be considered either in isolation or as a substitute for formally-defined financial measures or reports prepared in accordance with IFRS.

Quantitatively, EBITDA as defined above may be reconciled to IFRS-defined and reported Net Earnings by the deduction of the IFRS-defined and reported expense measures of interest, taxes, depreciation, and amortization. Net Earnings of Microbix for the years of fiscal 2021 through 2026 were C\$ 3.2, 1.8, 0.0, 3.5, (2.2), & (1.2) million respectively, as compared to EBITDA of C\$ 5.7, 3.6, 1.5, 5.5, 0.1, & (0.5) million for the same respective periods.

Debt-to-Equity, also known as D/E, is a financial ratio comprised of the firm’s total debt over its shareholders’ equity, sometimes used to assess financial leverage.

Current Ratio is a financial ratio comprised of the firm’s total current assets over its total current liabilities, sometimes used to assess financial liquidity.

Appendix regarding non-GAAP Financial Measures (Continued)



Reconciliation of Non-GAAP (non-IFRS) Measure

Quarterly EBITDA Fiscal 2021 to 2026

2021	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	\$130,819	\$807,463	\$1,516,178	\$778,930	\$3,233,390
Interest	262,403	265,996	273,182	801,624	1,603,205
Taxes	-	-	-	-	-
Depr'n & Amort'n	174,109	216,026	204,985	226,920	822,040
EBITDA	\$567,331	\$1,289,485	\$1,994,345	\$1,807,474	\$5,658,635

2024	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	\$2,455,379	\$377,730	\$246,746	\$440,324	\$3,520,179
Interest	114,485	81,326	(81,432)	119,890	234,269
Taxes	-	-	-	150,563	150,563
Depr'n & Amort'n	382,431	404,154	426,655	399,573	1,612,813
EBITDA	\$2,952,295	\$863,210	\$591,969	\$1,110,350	\$5,517,824

2022	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	\$880,778	\$733,489	\$638,502	(\$464,080)	\$1,788,689
Interest	240,750	203,125	170,454	129,961	744,290
Taxes	-	-	-	77,234	77,234
Depr'n & Amort'n	223,084	258,292	263,922	291,102	1,036,400
EBITDA	\$1,344,612	\$1,194,906	\$1,072,878	\$34,217	\$3,646,613

2025	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	\$856,962	\$20,664	(\$1,642,776)	(\$1,480,662)	(\$2,245,812)
Interest	113,129	157,962	156,489	168,314	595,894
Taxes	-	-	-	(55,726)	(55,726)
Depr'n & Amort'n	434,942	428,043	444,846	471,525	1,779,356
EBITDA	\$1,405,033	\$606,669	(\$1,041,441)	(\$896,549)	\$73,712

2023	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	(\$1,299,262)	\$31,616	(\$769,108)	\$1,997,271	(\$39,483)
Interest	97,078	91,319	102,490	90,749	381,636
Taxes	-	-	-	-	-
Depr'n & Amort'n	241,294	302,430	304,219	309,226	1,157,169
EBITDA	(\$960,890)	\$425,365	(\$362,399)	\$2,397,246	\$1,499,322

2026	Q1	Q2	Q3	Q4	FY Total
Net Income (Loss)	(\$1,167,177)				
Interest	180,196				
Taxes	-				
Depr'n & Amort'n	456,294				
EBITDA	(\$530,687)				